Clinical trials: AIDS and Infections
HIV Infections
A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants
This is an open-label, 2 part, single-dose and crossover study conducted to assess the relative bioavailability of a tablet compared to a capsule of GSK3640254 and to assess the effect of food on the GSK3640254 tablet in healthy…
- Trial name
- NCT04263142
- Testing
- GSK3640254 Tablet, GSK3640254 Capsule
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Cytomegalovirus Retinitis, HIV Infections
A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis
The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are already being treated for cytomegalovirus (CMV) retinitis.
- Trial name
- NCT00002169
- Testing
- Nelfinavir mesylate
- Where
- 8 sites in United States
- Sponsor
- Agouron Pharmaceuticals
Meningitis, Cryptococcal, HIV Infections
An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
To evaluate the safety and effectiveness of fluconazole as an intravenous dose as initial treatment for acute cryptococcal meningitis followed by oral therapy in AIDS and non-AIDS patients.
- Trial name
- NCT00002077
- Testing
- Fluconazole
- Where
- 4 sites in United States
- Sponsor
- Pfizer
Infection, Human Immunodeficiency Virus
A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects
Human immune virus (HIV) infected subjects may take mineral supplements in combination with their antiretroviral medications. Calcium and Iron supplementations are commonly used and both of these have the potential to interact…
- Trial name
- NCT01762995
- Testing
- Dolutegravir 50 mg, Calcium Carbonate 1200 mg, Ferrous Fumarate 324 mg
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Acquired Immunodeficiency Syndrome
Pharmacokinetic Study of Interaction Between Nevirapine and Methadone in HIV-1 Infected, Opioid-dependent Adults
The purpose of this study was to determine the effects of nevirapine treatment on the pharmacokinetics of methadone in HIV-1 infected, opioid-dependent adults who had been on a stable methadone maintenance therapy for at least…
- Trial name
- NCT00273988
- Testing
- nevirapine
- Where
- Ireland
- Volunteers
- 10 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients
The general aim is to evaluate the antiviral activity and safety of increasing doses of oral administered RTV-boosted BILR 355 BS (75 mg and 150 mg twice daily) in HIV-1-infected, NNRTI-experienced patients, followed by 28 day…
- Trial name
- NCT00294372
- Testing
- BILR 355 BS
- Where
- 11 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs
To evaluate the efficacy of Saquinavir-SGC combination with Zidovudine and Lamivudine in the treatment of HIV-1 infected patients with no previous anti-retroviral drug therapy.
- Trial name
- NCT00002367
- Testing
- Saquinavir, Lamivudine, Zidovudine
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy
The purpose of this study is to see if it is safe and effective to give HIV-positive patients L2-7001 (a type of interleukin-2) plus anti-HIV therapy.
- Trial name
- NCT00002449
- Testing
- Aldesleukin
- Where
- 23 sites in United States
- Volunteers
- 212 people
- Sponsor
- Chiron Corporation
HIV Infections
A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults
The purpose of this study was to evaluate the efficacy of GSK3640254 + DTG relative to lamivudine (3TC) + DTG in treatment-naïve adult participants living with human immunodeficiency virus (HIV)-1.
- Trial name
- DYNAMIC (NCT04900038)
- Testing
- GSK3640254, Dolutegravir, Lamivudine capsules
- Where
- 44 sites in United States, Argentina and 8 more
- Volunteers
- 85 people
- Sponsor
- ViiV Healthcare
HIV/AIDS
Epividian / AHF: Positive Pathways - HIV Retention in Care
The primary objective of this study is to evaluate the effectiveness of a clinical decision support system (CDSS) combined with enhanced patient contact to retain HIV+ patients in care with AIDS Healthcare Foundation.
- Trial name
- NCT04147832
- Testing
- Alert to provider
- Where
- United States
- Volunteers
- 10,521 people, healthy volunteers welcome
- Sponsor
- Epividian
HIV Infections
Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients
The purpose of this study is to see if two different doses of AG1549 plus other anti-HIV drugs are safe and effective in HIV-infected patients who are not taking anti-HIV drugs.
- Trial name
- NCT00004998
- Testing
- Lamivudine/Zidovudine, Capravirine, Nelfinavir mesylate
- Where
- 10 sites in United States, Dominican Republic
- Volunteers
- 30 people
- Sponsor
- Agouron Pharmaceuticals
HIV-1 Infection
Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)
This is a 2-part, phase 3 clinical study evaluating the antiretroviral activity and safety/tolerability of islatravir (ISL), doravirine (DOR), and a fixed dose combination (FDC) of DOR/ISL (also known as MK-8591A) in heavily…
- Trial name
- NCT04233216
- Testing
- ISL, DOR, DOR/ISL
- Where
- 98 sites in United States, Australia and 16 more
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1 Infection
Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants
The primary objective of the study is to investigate the short-term antiviral potency of bictegravir at multiple doses in antiretroviral (ART) treatment-naive adult participants and participants who are ART-experienced but…
- Trial name
- NCT02275065
- Testing
- Bictegravir
- Where
- 16 sites in United States
- Volunteers
- 23 people
- Sponsor
- Gilead Sciences
Infection, Human Immunodeficiency Virus I
A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
This is a single-center, open-label, three-period, fixed-sequence cross over study in healthy adult subjects. A total of approximately 16 healthy subjects will be enrolled to provide data from 12 evaluable subjects.
- Trial name
- NCT01283100
- Testing
- GSK1349572, GSK2248761
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Cytomegalovirus Retinitis, HIV Infections
A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis
To determine the MTD and dose-limiting toxicities of a regimen of therapeutic ganciclovir, antiretroviral therapy, and recombinant interleukin-2 (aldesleukin; Proleukin) as an immune adjuvant in HIV-seropositive patients.
- Trial name
- NCT00002321
- Testing
- Aldesleukin
- Where
- United States
- Sponsor
- Chiron Corporation
HIV Infections
Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir
The aim of this cross-over study is to compare the relative bioavailability and pharmacokinetic parameters of both 10 mg conventional tablets and 5 mg dispersible tablets of dolutegravir (DTG) with that of 25 mg or 50 mg…
- Trial name
- NCT03095638
- Testing
- Conventional dolutegravir 10 mg tablet, Conventional dolutegravir 50 mg tablet, Dispersible dolutegravir 5 mg tablet
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus
MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)
This is a single-dose clinical study to evaluate the safety, tolerability, pharmacokinetics, and anti-retroviral activity of MK-8527 in antiretroviral therapy (ART)-naïve participants living with human immunodeficiency virus type…
- Trial name
- NCT05494736
- Testing
- MK-8527
- Where
- 4 sites in Romania, South Africa
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)
This study will investigate the safety and efficacy of raltegravir as a therapy for HIV-infected patients failing current therapy with 3-class antiviral resistance.
- Trial name
- NCT00293267
- Testing
- raltegravir potassium
- Volunteers
- 352 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients With Late-Stage HIV Disease
The purpose of this study is to see if it is safe and effective to give WF10 to adults with late-stage HIV disease. WF10 is suspected to help the immune system fight infection and slow HIV disease progression.
- Trial name
- NCT00002244
- Testing
- WF10
- Where
- 32 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- OXO Chemie
HIV-1 Infection
A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
This is an observational, non-comparative, multicenter, open-label study. Participants will be treated with Raltegravir according to standard clinical practice, and monitored over a total period of 96 weeks.
- Trial name
- WIP (NCT01213316)
- Testing
- Raltegravir
- Volunteers
- 451 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.